Invalidation of a Commercially Available Human 5α-Dihydrotestosterone Immunoassay

    September 2013 in “ Steroids
    Joshua F. Yarrow, Darren T. Beck, Christine F. Conover, Luke A. Beggs, Bruce A. Goldberger, Stephen E. Borst
    TLDR The DHT immunoassay is unreliable due to high cross-reactivity with testosterone.
    The study invalidated a commercially available dihydrotestosterone (DHT) immunoassay due to significant cross-reactivity with testosterone, which ranged from 18% to 99%. This cross-reactivity led to DHT concentrations being overestimated by 79% to over 1000% compared to the gold-standard LC–MS/MS method. The immunoassay failed to detect reductions in DHT following finasteride treatment, unlike LC–MS/MS. The study involved older hypogonadal men in a 12-month trial, highlighting that the immunoassay's results were not reliable for assessing DHT in biological fluids containing testosterone.
    Discuss this study in the Community →

    Research cited in this study

    6 / 6 results